Revlimid lenalidomide: Updated Phase III data

Updated data from the double-blind, U.S. Phase III CALGB-100104 trial in 460 patients showed that 5-15 mg/day Revlimid as maintenance therapy following autologous stem cell transplantation led to a significantly lower rate of disease progression at a median follow-up of 17 months vs. placebo (19.9% vs. 41.5%, p<0.0001). Median time to progression was significantly higher for Revlimid-treated patients vs. placebo (42.3 vs. 21.8 months, p<0.0001). Celgene also reported that 15 patients treated with Revlimid developed secondary malignancies compared to 6 patients receiving placebo. Data were presented at the American Society of Hematology meeting in Orlando. The trial was sponsored by NIH's National Cancer Institute (NCI). ...